Lecture 5- antibiotics.ppt

Antimicrobial prophylaxis

1. Antimicrobial Agents
Prof. Khaled H. Abu-Elteen

2. What is an Antibiotic?
•An antibiotic is a selective poison.
•It has been chosen so that it will kill the desired
bacteria, but not the cells in your body. Each
different type of antibiotic affects different bacteria
in different ways.
•For example, an antibiotic might inhibit a bacteria's
ability to turn glucose into energy, or the bacteria's
ability to construct its cell wall. Therefore the
bacteria dies instead of reproducing.

3. Antibiotics
•Substances produced by various species
of microorganisms: bacteria, fungi,
actinomycetes-to suppress the growth of
other microorganisms and to destroy them.
Today the term antibiotics extends to include
synthetic antibacterial agents: sulfonamides
and quinolones.

4. Where do antibiotics come from?
•Several species of fungiincluding Penicillium
and Cephalosporium
•E.g. penicillin, cephalosporin
–Species of actinomycetes, Gram positive filamentous
bacteria
•Many from species of Streptomyces
–Also from Bacillus, Gram positive spore formers
–A few from myxobacteria, Gram negative bacteria
–New sources explored: plants, herps, fish

6. Selective toxicity
•The more distantly related the invader, the more
targets available for the drug to hit
–The less likelihood of direct toxic effects.
•Prokaryotes biochemically least similar
•Fungi and Protozoa are eukaryotes, so more closely
related to humans.
•Helminths (worms) also animals
•Viruses use our own cell machinery
•Cancer cells ARE our cells.

8. History of Antimicrobial Therapy
•1909 Paul Ehrlich
–Differential staining of tissue, bacteria
–Search for magic bullet that would attack
bacterial structures, not ours.
–Developed salvarsan, used against syphilis.

9. •1929 Penicillindiscovered by Alexander
Fleming
•1940 Florey and Chain mass produce penicillin for
war time use, becomes available to the public.
•1935 Sulfadrugs discovered
•1944 Streptomycindiscovered by Waksman
from Streptomyces griseus

10. Sir Alexander Fleming

11. Fleming’s Petri Dish

12. Historical distinctions
•Antibiotics: substances produced by organisms
that have inhibitory effects on other organisms.
–Penicillin, streptomycin
•Synthetic drugs: produced in a lab.
–Salvarsan, sulfa drugs
•Nowadays, most antimicrobials are semi-
synthetic
–Distinction between “antibiotics” and “synthetic
drugs” slowly being abandoned.

13. Selective toxicity means safer for
host
•Antibiotics generally have a low MIC
–Minimum inhibitory concentration
–Effective at lower doses
•Good therapeutic index( Ti)
–Safer; larger quantity must be administered before
harmful side effects occur.
e.g. Ti = LD
50/ ED
50
Where LD = lethal dose
ED = effective dose

14. Bacteriostatic vs. Bactericidal
•Antibiotics differ by mode of action
•Bacteriostatic compounds inhibit the growth of
bacteria
–Holds invaders in check; host immune system does
the killing
•Bactericidal compounds directly kill the bacteria
•Location and severity of infection affect choice of
antibiotic
–E.g. CNS infection calls for bactericidal treatment.

15. VI. Antibacterial Agents
• A. Inhibitors of cell wall synthesis
• 1. Penicillins
• 2. Cephalosporins
• 3. Other antibacterial agents that act on cell walls
• B. Disrupters of cell membranes
• 1. Polymyxins
• 2. Tyrocidins
• C. Inhibitors of protein synthesis
• 1. Aminoglycosides
• 2. Tetracyclines
• 3. Chloramphenicol
• 4. Other antibacterial agents that affect protein synthesis
• a. Macrolides
• b. Lincosamides
• D. Inhibitors of nucleic acid synthesis
• 1. Rifampin
• 2. Quinolones
• E. Antimetabolites and other antibacterial agents
• 1. Sulfonamides
• 2. Isoniazid
• 3. Ethambutol
• 4. Nitrofurans

17. Antibiotic Mechanisms of Action
Transcription
Translation
Translation
Alteration of
Cell Membrane
Polymyxins
Bacitracin
Neomycin

18. Review and Overview of Bacterial Targets
•Bacterial cell walls
–Except for Mycoplasmaand relatives, all
bacteria of the Domain Eubacteria possess
peptidoglycan
–Peptidoglycan provides shape and structural
support to bacterial cells
–Bacterial cytoplasm is generally hypertonic
compared to their environment
•Net flow of water: into cell
•Wall under high osmotic pressure

19. Cell walls continued
•Chemical structure of peptidoglycan
contributes to its function
–Polysaccharide chains composed of 2
alternating sugars, N-acetylglucosamine(NAG)
and N-acetylmuramic acid(NAM)
–Cross-linked in 3 dimensions with amino acid
chains
–A breach in peptidoglycan endangers the
bacterium

20. Peptidoglycan Molecule
Cross links are both horizontal and vertical between
glycan chains stacked atop one another.

21. There is no molecule similar to
peptidoglycan in humans, making
drugs that target cell wall
synthesis very selective in their
toxicity against bacteria.

22. Gram positive & Gram Negative
•Gram positive bacteria have a thick cell wall
–Peptidoglycan directly accessible from environment
•Gram negative bacteria have a different wall
–Thin layerof peptidoglycan
–Surrounded by an outer membranecomposed of
lipopolysaccharide, phospholipids, and proteins
–Outer membrane is a barrier to diffusion of molecules
including many antibiotics
•Some hydrophobic antibiotics may diffuse in.
•Porins allow passage of only some antibiotics

23. Gram negative cell structure

24. 1-Inhibition of cell wall synthesis
•beta-lactam containing antibiotics inhibit
transpeptidase; bacteria cannot synthesize
reinforced cell wall and they lyse when they try to
grow
•Vancomycin and cyclo-Serinhibit specific binding
of Ala’s in crossbridges to transpeptidase in many
gram+ bacteria
•Bacitracin inhibits secretion of NAG and NAM
subunits
•All of these only kill growing bacteria

25. Cell wall synthesis inhibitors

26. Penicillins
•Penicillins contain a b-lactam ring which inhibits the
formation of peptidoglycan crosslinks in bacterial cell
walls (especially in Gram-possitive organisms)
•Penicillins are bactericidal but can act only on dividing
cells
•They are not toxic to animal cells which have no cell
wall

28. Synthesis of Penicillin
b-Lactams produced by fungi, some ascomycetes,
and several actinomycete bacteria
b-Lactams are synthesized from amino acids
valineand cysteine

29. bLactam Basic Structure

30. Penicillins
Clinical Pharmacokinetics
•Penicillins are poorly lipid soluble and do
not cross the blood-brain barrier in
appreciable concentrations unless it is
inflamed (so they are effective in
meningitis)
•They are actively excreted unchanged by
the kidney, but the dose should be reduced
in severe renal failure

31. Penicillins
Resistance
•This is the result of production of b-lactamase
enzyme in the bacteria which destroys the b-
lactam ring
•It occurs in e.g. Staphylococcus aureus,
Haemophilus influenzae andNeisseria
gonorrhoea

32. Penicillins
Examples
•There are now a wide variety of penicillins,
which may be acid labile(i.e. broken down by
the stomach acid and so inactive when given
orally) or acid stable, or may be narrow or
broad spectrum in action

33. Penicillins
Examples
•Benzylpenicillin (Penicillin G) is acid labile
and b-lactamase sensitive and is given only
parenterally
•It is the most potent penicillin but has a
relatively narrow spectrum covering
Strepptococcus pyogenes, S. pneumoniae,
Neisseria meningitis or N. gonorrhoeae,
treponemes, Listeria, Actinomycetes,
Clostridia

34. Penicillins
Examples
•Phenoxymethylpenicillin (Penicillin V)is
acid stable and is given orally for minor
infections
•it is otherwise similar to benzylpenicillin

35. Penicillins
Examples
•Ampicillin is less active than
benzylpenicillin against Gram-possitive
bacteria but has a wider spectrum including
(in addition in those above) Strept. faecalis,
Haemophilus influenza, and some E. coli,
Klebsiella and Proteusstrains
•It is acid stable, is given orally or
parenterally, but is b-laclamase sensitive

36. Penicillins
Examples
•Amoxycillin is similar but better absorbed
orally
•It is sometimes combined with clavulanic
acid, which is a b-lactam with little
antibacterial effect but which binds strongly
to b-lactamase and blocks the action of b-
lactamase in this way
•It extends the spectrum of amoxycillin

37. Penicillins
Adverse effects
•Allergy : Patient should be always asked
about a history of previous exposure and
adverse effects
•Superinfections (e.g.caused byCandida)
•Diarrhoea : especially with ampicillin, less
common with amoxycillin
•Rare: haemolysis, nephritis

38. Penicillins
Drug interactions
•The use of ampicillin (or other broad-
spectrum antibiotics) may decrease the
effectiveness of oral conraceptives by
diminishing enterohepatic circulation

39. Cephalosporins
•They also owe their activity to b-lactam ring and
are bactericidal.
•Produced from a fungus Cephalosporium
acremonium.
•Good alternatives to penicillins when a broad -
spectrum drug is required
•should not be used as first choice unless the
organism is known to be sensitive

40. Cephalosporins
•BACTERICIDAL-modify cell wall synthesis
•Interfere at the final step of peptidoglycan
synthesis ( Transpeptidation)
•CLASSIFICATION-first generation are early
compounds
•Second generation-resistant to β-lactamases
•Third generation-resistant to β-lactamases &
increased spectrum of activity
•Fourth generation-increased spectrum of activity

41. Cephalosporins
•FIRST GENERATION-eg cefadroxil, cefalexin,
Cefadrine-most active vs gram +ve cocci. An
alternative to penicillins for staph and strep
infections; useful in UTIs
•SECOND GENERATION -eg cefaclor and
cefuroxime. Active vs enerobacteriaceae eg E.
coli, Klebsiellaspp,proteus spp. May be active vs
H influenzae and N meningtidis

42. Cephalosporins
•THIRD GENERATION -eg cefiximeand other
I.V.scefotaxime,ceftriaxone,ceftazidine.Very
broad spectrum of activity inc gram -ve rods, less
activity vs gram +ve organisms.
•FOURTH GENERATION -cefpirome better vs
gram +ve than 3rd generation. Also better vs gram
-ve esp enterobacteriaceae & pseudomonas
aerugenosa.I.V. route only

44. Cephalosporins
Adverse effects
•Allergy (10-20% of patients with penicillin
allergy are also allergic to cephalosporins)
•Nephritis and acute renal failure
•Thrombophlebitis
•Superinfections
•Gastrointestinal upsets when given orally

45. Vancomycin
•This interferes with bacterial cell wall
formationand is not absorbed after oral
administration and must be given
parenterally.
•It is excreted by the kidney.
•It is used i.v. to treat serious or resistant
Staph. aureusinfections and for prophylaxis
of endocarditis in penicillin-allergic people.

46. Vancomycin
Adverse effects
•Its toxicity is similar to aminoglycoside and
likewise monitoring of plasma
concentrations is essential.
•Nephrotoxicity
•Allergy

47. 2-Inhibition of protein synthesis
•Aminoglycosides(bactericidal): streptomycin,
kanamycin, gentamicin, tobramycin, amikacin,
netilmicin, neomycin
•Macrolides
•Chloramphenicol, Lincomycin, Clindamycin
(bacteriostatic)

48. Protein synthesis inhibitors
•Need to affect bacteria, not mitochondria
•Aminoglycosides (streptomycin, gentamicin)
change shape of 30S ribosome subunit
•Tetracycline blocks access to A site of 30S subunit
•Chloramphenicol block peptide bond formation
from 50S subunit
•Macrolides (erythromycin) block 50S subunit
action
•Antisense NAs bind to beginning of mRNA and
block translation

49. Protein synthesis inhibitors

50. Ribosomes: site of protein
synthesis
•Prokaryotic ribosomes are 70S;
–Large subunit: 50 S
•33 polypeptides, 5S RNA, 23 S RNA
–Small subunit: 30 S
•21 polypeptides, 16S RNA
•Eukaryotic are 80S
Large subunit: 60 S
•50 polypeptides, 5S, 5.8S, and 28S RNA
–Small subunit: 40S
•33 polypeptides, 18S RNA

51. Differences in structure between
prokaryotic and eukaryotic
ribosomes make antibiotics that
target protein synthesis fairly
selectively toxic against bacteria.

52. Aminoglycosides (bactericidal)
streptomycin, kanamycin, gentamicin, tobramycin, amikacin,
netilmicin, neomycin (topical)
•Mode of action-The aminoglycosides irreversibly bind to the 16S
ribosomal RNA and freeze the 30S initiation complex (30S-mRNA-
tRNA) so that no further initiation can occur. They also slow down
protein synthesis that has already initiated and induce misreading of
the mRNA. By binding to the 16 S r-RNA the aminoglycosides
increase the affinity of the A site for t-RNA regardless of the anticodon
specificity. May also destabilize bacterial membranes.
•Spectrum of Activity-Many gram-negative and some gram-positive
bacteria
•Resistance-Common
•Synergy-The aminoglycosides synergize with β-lactam antibiotics.
The β-lactams inhibit cell wall synthesis and thereby increase the
permeability of the aminoglycosides.

53. Aminoglycosides
Clinical pharmacokinetics
•These are poorly lipid soluble and,
therefore, not absorbed orally
•Parenteral administration is required for
systemic effect.
•They do not enter the CNS even when the
meninges are inflamed.
•They are not metabolized.

54. Aminoglycosides
Clinical pharmacokinetics
•They are excreted unchanged by the kidney
(where high concentration may occur,
perhaps causing toxic tubular demage) by
glomerular filtration (no active secretion).
•Their clearance is markedly reduced in
renal impairment and toxic concentrations
are more likely.

55. Aminoglycosides
Resistance
•Resistance results from bacterial enzymes
which break down aminoglycosides or to
their decreased transport into the cells.

56. Aminoglycosides
Examples
•Gentamicin is the most commonly used,
covering Gram-negative aerobes, e.g.
Enteric organisms (E.coli, Klebsiella, S.
faecalis, Pseudomonas and Proteus spp.)
•It is also used in antibiotic combination
against Staphylococcus aureus.
•It is not active against aerobic Streptococci.

57. Aminoglycosides
Examples
•Tobramycin: used for pseudomonas and for
some gentamicin-resistant organisms.
•Some aminoglycosides,e.g. Gentamicin, may
also be applied topically for local effect, e.g. In
ear and eye ointments.
•Neomycinis used orally for decontamination of
GI tract.

58. Aminoglycosides
Adverse effects
•The main adverse effects are:
Nephrotoxicity
Toxic to the 8th cranial nerve (ototoxic),
especially the vestibular division.
•Other adverse effects are not dose related,
and are relatively rare, e.g. Allergies.

59. Macrolides (bacteriostatic)
erythromycin, clarithromycin, azithromycin, spiramycin
•Mode of action-The macrolides inhibit
translocationby binding to 50 S ribosomal subunit
•Spectrum of activity-Gram-positive bacteria,
Mycoplasma, Legionella(intracellular bacterias)
•Resistance -Common

60. Macrolides
Examples and clinical pharmacokinetics
•Erythromycin is acid labile but is given as
an enterically coated tablet
•It is excreted unchanged in bile and is
reabsorbed lower down the gastrointestinal
tract.
•It may be given orally or parenterally

61. Macrolides
Examples and clinical pharmacokinetics
•Macrolides are widely distributed in the body
except to the brain and cerebrospinal fluid
•The spectrum includes Staphylococcus aureus,
Streptococcuss pyogenes, S. pneumoniae,
Mycoplasma pneumoniae and Chlamydia
infections.

62. Macrolides –side effects
•Nauzea, vomitus
•Allergy
•Hepatitis, ototoxicity
•Interaction with cytochrome P450 3A4
(inhibition)

63. Chloramphenicol, Lincomycin,
Clindamycin(bacteriostatic)
•Mode of action-These antimicrobials bind to the 50S
ribosome and inhibit peptidyl transferase activity.
•Spectrum of activity-Chloramphenicol -Broad range;
Lincomycin and clindamycin -Restricted range
•Resistance-Common
•Adverse effects-Chloramphenicol is toxic (bone marrow
suppression) but is used in the treatment of bacterial
meningitis.

64. Clindamycin
•Clindamycin, although chemically distinct,
is similar to erythromycin in mode of action
and spectrum.
•It is rapidly absorbed and penetrates most
tissues well, except CNS.
•It is particularly useful systematically for S.
aureus(e.g.osteomyelitis as it penetrates
bone well) and anaerobic infections.

65. Clindamycin
Adverse effects
•Diarrhoea is common.
•Superinfection with a strain of Clostridium
difficilewhich causes serious inflammation
of the large bowel (Pseudomembranous
colitis)

66. Chloramphenicol
•This inhibits bacterial protein synthesis.
•It is well absorbed and widely distributed ,
including to the CNS.
•It is metabolized by glucoronidation in the
liver.
•Although an effective broad-spectrum
antibiotics, its uses are limited by its serious
toxicity.

67. Chloramphenicol
•The major indication is to treat bacterial
meningitis caused by Haemophilus
influenzae, or toNeisseria menigitidisor if
organism is unknown.It is also specially
used for Rikettsia (typhus).

68. Chloramphenicol
Adverse effects
•A rare anemia, probably immunological in
origin but often fatal
•Reversible bone marrow depression caused
by its effect on protein synthesis in humans
•Liver enzyme inhibition

69. Tetracyclines(bacteriostatic)
tetracycline, minocycline and doxycycline
•Mode of action-The tetracyclines reversibly bind to the
30S ribosome and inhibit binding of aminoacyl-t-RNA to
the acceptor site on the 70S ribosome.
•Spectrum of activity-Broad spectrum; Useful against
intracellular bacteria
•Resistance-Common
•Adverse effects-Destruction of normal intestinal flora
resulting in increased secondary infections; staining and
impairment of the structure of bone and teeth.

71. Tetracyclines
Examples and clinical pharmacokinetics
•Tetracycline, oxytetracyclinehave short
half-lives.
•Doxycycline has a longer half-life and can
be given once per day.
•These drugs are only portly absorbed.
•They bind avidly to heavy metal ions and so
absorption is greatly reduced if taken with
food, milk, antacids or iron tablets.

72. Tetracyclines
Examples and clinical pharmacokinetics
•They should be taken at least half an hour before
food.
•Tetracyclines concentrate in bones and teeth.
•They are excreted mostly in urine, partly in bile.
•They are broad spectrum antibiotics, active against
most bacteria except Proteus or Pseudomonas.
•Resistance is frequent

73. Tetracyclines
Adverse effects
•Gastrointestinal upsets
•Superinfection
•Discolouration and deformity in growing
teeth and bones(contraindicated in
pregnancy and in children < 12 years)
•Renal impairment(should be also avoided
in renal disease)

74. 3-Metabolic inhibitors
•Sulfonamides (sulfanilamide) are structural analogs
of PABA, a molecule crucial for Nucleic acid
synthesis
•humans do not synthesize dihydropteroic acidfrom
PABA
•Trimethoprim interferes in next step DHF -> THF

75. Mechanism of Action
ANTIMETABOLITE ACTION
(cont’d)
tetrahydrofolic acid

76. Sulfonamides and trimethoprim
•Sulfonamides are rarely used alone today.
•Trimethoprim is not chemically related but
is considered here because their modes of
action are complementary.

77. Sulfonamides, Sulfones(bacteriostatic)
•Mode of action-These antimicrobials are analogues of
para-aminobenzoic acid and competitively inhibit
formation of dihydropteroic acid.
•Spectrum of activity-Broad range activity against gram-
positive and gram-negative bacteria; used primarily in
urinary tract and Nocardiainfections.
•Resistance-Common
•Combination therapy-The sulfonamides are used in
combination with trimethoprim; this combination blocks
two distinct steps in folic acid metabolismand prevents the
emergence of resistant strains.

78. Trimethoprim, Methotrexate,
(bacteriostatic)
•Mode of action-These antimicrobials binds to
dihydrofolate reductase and inhibit formation of
tetrahydrofolic acid.
•Spectrum of activity-Broad range activity against gram-
positive and gram-negative bacteria; used primarily in
urinary tract and Nocardiainfections.
•Resistance-Common
•Combination therapy-These antimicrobials are used in
combination with the sulfonamides; this combination
blocks two distinct steps in folic acid metabolism and
prevents the emergence of resistant strains.

79. p-aminobenzoic acid + Pteridine
Dihydropteroic acid
Dihydrofolic acid
Tetrahydrofolic acid
Pteridine
synthetase
Dihydrofolate
synthetase
Dihydrofolate
reductase
Thymidine
Purines
Methionine
Trimethoprim
Sulfonamides

80. Sulfonamides and trimethoprim
Mode of action
•Folate is metabolized by enzyme
dihydrofolate reductase to the active
tetrahydrofolic acid.
•Trimethopriminhibits this enzyme in
bacteria and to a lesser degree in animal s,
as the animal enzyme is far less sensitive
than that in bacteria.

81. Sulfonamides and trimethoprim
Clinical pharmacokinetics
•It is the drug of choice for the treatment and
prevention of pneumonia caused by
Pneumocystis cariniiin immunosupressed
patients.
•Trimethoprim is increasingly used alone for
urinary tract and upper respiratory tract
infections, as it is less toxic than the
combination and equally effective.

82. Sulfonamides and trimethoprim
Adverse effects
•Gastrointestinal upsets
•Less common but more serious:
sulfonamides: allergy, rash, fever,
renal toxicity
trimethoprim: anemia,thrombocytopenia
-cotrimoxazole: aplastic anemia

83. 4-Interference with nucleic acid
synthesis
•Bacterial DNA is negatively supercoiled
–Supercoiling is maintained by gyrase, a type II
topoisomerase.
–Inhibition of gyrase and type IV topoisomerase interferes
with DNA replication, causes cell death
–Eukaryotic topoisomerases differ in structure

84. Quinolones(bactericidal)
nalidixic acid, ciprofloxacin, ofloxacin, norfloxacin,
levofloxacin, lomefloxacin, sparfloxacin
•Mode of action-These antimicrobials bind to the A
subunit of DNA gyrase (topoisomerase) and prevent
supercoiling of DNA, thereby inhibiting DNA synthesis.
•Spectrum of activity-Gram-positive cocci and urinary
tract infections
•Resistance-Common for nalidixic acid; developing for
ciprofloxacin

85. (cont’d)
Mechanism of Action
INHIBITION OF DNA/RNA SYNTHESIS

86. Quinolones
•The quinolones are effective but expensive
antibiotics.
•With increased use, resistance to these
drugs is becoming more common.

87. Quinolones
Examples and clinical pharmacokinetics
•Nalidixicacid, the first quinolone, is used as
a urinary antiseptic and for lower urinary
tract infections, as it has no systemic
antibacterial effect.
•Ciprofloxacinis a fluoroquinolone with a
broad spectrum against Gram-negative
bacilli and Pseudomonas,

88. Quinolones
Examples and clinical pharmacokinetics
•It can be given orally or i.v. to treat a wide
range of infections, including respiratory
and urinary tract infections as well as more
serious infections, such Salmonella.
•Activity against anaerobic organism is poor
and it should not be first choice for
respiratory tract infections.

89. Quinolones
Adverse effects
•Gastrointestinal upsets
•Fluoroquinolones may block the inhibitory
neurotransmitter, and this may cause confusion
in the elderly and lower the fitting threshold.
•Allergy and anaphylaxis

90. Quinolones
Adverse effects
•Possibly damage to growing cartilage: not
recommended for pregnant women and
children

91. Metronidazole
•Metronidazole binds to DNA and blocks
replication.
Pharmacokinetics
•It is well absorbed after oral or rectal
administration and can be also given i.v.
•It is widely distributed in the body
(including into abscess cavities)
•It is metabolized by the liver.

92. Metronidazole
Uses
•Metronidazole is active against anaerobic
organisms (e.g. Bacteroides, Clostridia),
which are encountered particularly in
abdominal surgery.
•It is also used against Trichomonas, Giardia
and Entamoeba infections.

93. Metronidazole
Uses
•Increasingly, it is used as part of treatment
of Helicobacter pyloris infestion of the
stomach and duodenum associated with
peptic ulcer disease.
•It is used also to treat a variety of dental
infections, particularly dental abscess.

94. Metronidazole
Adverse effects
•Nausea, anorexia and metallic taste
•Ataxia
•In patients, who drink alcohol, may occur
unpleasant reactions. They should be
advised not to drink alcohol during a
treatment.

95. Nitrofurantoin
•This is used as a urinary antiseptic and to
treat Gram-negative infections in the lower
urinary tract. It is also used against
Trypanosoma infections.
•It is taken orally and is well absorbed and is
excreted unchanged in the urine.

96. Nitrofurantoin
Adverse effects
•Gastrointestinal upsets
•Allergy
•Polyneuritis

97. Fucidin
•Fucidin is active only against Staphylococcus
aureus(by inhibiting bacterial protein
synthesis) and is not affected b-lactamase.
•It is usually only used with flucloxacillin to
reduce the development of resistance.
•It is well absorbed and widely distributed,
including to bone
•It can be given orally or parenterally.
•It is metabolized in the liver.

98. Antibiotics for leprosy
•Leprosy is caused by infection with
Mycobacteria leprae.
•A mixture of drugs are used to treat leprosy,
depending on the type and severity of the
infection and the local resistance patterns.

99. Antibiotics for leprosy
•Rifampicin is used, which is related to the
sulphoamides.
•Rifampicin and Rifamycin block synthesis
of m-RNA.
•Its adverse effects include haemolysis,
gastrointestinal upsets and rashes.

100. 5-Cell membranes as targets
•Bacterial cell membranes are essentially the
same in structure as those of eukaryotes
–Antibiotics also affect Gram neg. cell walls, ie.
Outer membrane together with cell membrane
–Anti-membrane drugs are less selectively toxic
than other antibiotics.
–Many antifungal drugs ( Polyenes as Amphotericin
B, Nystatin) make use of cell membrane
differences.

101. Cell membrane disruptors
•Amphotericin Bbinds to ergosterol of cell
membranes of fungi, causing lysis of cell
•Azoles(fluconazole) and allyamines
(turbinafine) block ergosterol synthesis
•Polymixindisrupts bacterial cell membranes,
but is toxic to people

102. Antibiotic resistance
•Inherent: Outer membrane of Gram negative
bacteria, wall-less bacteria.
•Mutations: change in transport protein, ribosome,
enzyme, etc. Normally harmful mutations are
selected FOR in the presence of antibiotic.
•Plasmids: through conjugation, genetic information
allowing cell to overcome drug.

103. Mechanisms of drug resistance
•Alteration of target: active site of enzyme changes,
ribosome changes.
•Alteration of membrane permeability: transport
protein changes, drug no longer enters; drug that
does enter is actively pumped out.
•Enzymatic destruction of drug: penicillinases (beta
lactamases)
•“End around” inhibitor: bacteria learns to use new
metabolic pathway, drug no longer effective.

104. Drug resistance
•Beta-lactamase is now wide-spread and often is
found on plasmids
•New synthetic versions of penicillin have been
developed that are not cleaved by beta-lactamase
•Other resistances develop

105. Spectrum of action of antimicrobials

106. Spectrum
•When specific testing is not done or delayed,
antibiotic with a broad spectrumis administered
–Broad spectrum antibiotics can penetrate Gram –outer
membranes, resist inactivation, etc.
–Shotgun: better chance of inhibiting pathogen
•Death of normal microbiota results in overgrowth of
resistant bacteria (endogenous infection;
“superinfection”) or allows invasion by outside
opportunists.

107. Drug administration
•Antibiotics administered oral, i.v., i.m.,i.p
–Same caveats apply, i.e. acid instability, delayed
absorption with food for oral
–i.v. gives higher, quicker concentrations,
reaches more compartments with sufficient
dose quickly

108. Combination therapy
•Some valuable reasons why combination
therapy is used
–Synergistic effectsbetween two drugs
–Polymicrobial infections, e.g. abdominal
injuries
–Avoid Antagonistic effects.

109. Chemotherapy for viruses

110. •Antifungal Agents
• A. Imidazoles and triazoles
• B. Polyenes
• 1. Amphotericin B
• 2. Nystatin
• C. Griseofulvin
• D. Other antifungal agents
• 1. Flucytosine
• 2. Tolnaftate
• 3. Terbinafine
•Antiviral Agents
• A. Purine and pyrimidine analogues
• 1. Idoxuridine and trifluridine
• 2. Vidarabine
• 3. Ribavirin
• 4. Acyclovir
• 5. Ganciclovir
• 6. Zidovudine
• B. Amantadine
• C. Treatment of AIDS
•

113. Antiviral drugs
•Antiviral chemotherapy is still in its
infancy.
•Viruses are more difficult ‘targets’ than
bacteria: they are most vulnerable during
reproduction, but all use host cell organelles
and enzymes to do this, so that antiviral
compounds are often as toxic to host cells
as to virus.

114. Antiviral drugs (cont.)
•Current antiviral drugs are thought to work
in one of the following ways:
1-inhibition of viral ‘uncoating’ shortly
after penetration into the cell; they are
best for prophylaxis or very early in the
disease course (e.g.amantadine)
2-interference with viral RNA
synthesis and function (e.g. ribavirin)

115. Antiviral drugs (cont.)
3-interference with DNA synthesis (e.g.
cytarabine and Vidarabine)
4-inhibition of viral DNA polymerase
(e.g.acyclovir, Penciclovir and gancyclovir)
5-inhibition of reverse transcriptase at
retroviruses such as HIV (e.g.zidovudine,
Azidothymidine(AZT))

116. Acyclovir
Mode of action
•It is active against Herpes simplex and
Herpes zoster.
•Acyclovir targets virus-infected cells quite
specifically, and inhibit viral replication and
this explains the drug`s relatively low
toxicity.

117. Acyclovir (cont.)
Therapeutic uses
•It is the drug of first choice for Herpes
simplex and zoster infections, because of
thegreat efficacy and lower toxicity than
the alternatives.
•Thedrug has little activity against
cytomegalovirus or Epstein-Barr virus.

118. Acyclovir (cont.)
Therapeutic uses
•Herpes simplexinfections of skin, mucous
membranes and cornea
•Life-threatening Herpes simplexinfections;
acyclovir i.v. reduces mortality
•Herpes zoster that is less sensitive to
acyclovir than H. simplex .It is used for
early topic or oral treatment of zoster.

119. Zidovudine (AZT)
Mode of action
•HIV virus is an RNA virus capable of including
the synthesis of a DNA transcript of its genome,
which can then become integrated into the host
cell`s DNA, thereby allowing viral replication.
•Synthesis of the initial DNA transcript involves
the enzyme reverse transcriptase.
•Zidovudine is a potent inhibitor of reverse
transcriptase.

120. Purine and pyrimidine analogues
Mode of action
•These drugs are effective against DNA
viruses
•The compounds structurally resemble
purine and pyrimidine nucleosides
•The resulting DNA molecule is more easily
fragmented, leading to transcription errors.
•They also inhibit viral DNA polymerase.

121. Purine and pyrimidine analogues
Examples and clinical pharmacokinetics
•Idoxuridine: it is not absorbed from the gut,
and is used topically
•Vidarabine: cannot be given orally because
it is metabolized in the gut
-it is usually given i.v. or topically

122. Purine and pyrimidine analogues
Therapeutic uses
•Idoxuridine: may be used topically for
Herpes simplex and zoster but is too toxic
for systemic use and has largely been
supplanted by aciclovir
•Vidarabine: may be used for life-
threatening systemic Herpes infections

123. Zone of Inhibition
•Around the fungal
colony is a clear zone
where no bacteria are
growing
•Zone of inhibition due
to the diffusion of a
substance with
antibiotic properties
from the fungus

124. Susceptibility vs. Resistance
of microorganisms to
Antimicrobial Agents
•Success of therapeutic outcome depends on:
•Achieving concentration of ATB at the site of
infection that is sufficient to inhibit bacterial
growth.
•Host defenses impaired-bactericidal agents
•Complete ATB-mediated killing is necessary

125. Susceptibility vs. Resistance
(cont.)
•Dose of drug has to be sufficient to produce effect
inhibit or kill the microorganism:
•However concentration of the drug must remain
below those that are toxic to human cells –
•If can be achieved –microorganism susceptible to
the ATB
•If effective concentration is higher than toxic-
microorganism is resistant

126. Susceptibility Tests
1.Broth dilution-MIC test
2.Agar dilution-MIC test

127. 32 ug/ml16 ug/ml8 ug/ml4 ug/ml2 ug/ml1 ug/ml
Sub-culture to agar medium
MIC = 8 ug/ml
MBC = 16 ug/ml
Minimal Inhibitory Concentration (MIC)
vs.
Minimal Bactericidal Concentration (MBC)

128. Susceptibility Tests
3.Agar diffusion
Kirby-Bauer Disk Diffusion Test
(cont’d)

129. Susceptibility Tests
“Kirby-Bauer Disk-plate test”
Diffusion depends upon:
1.Concentration
2.Molecular weight
3.Water solubility
4.pH and ionization
5.Binding to agar
(cont’d)

130. Susceptibility Tests
“Kirby-Bauer Disk-plate test”
Zones of Inhibition (~ antimicrobial
activity) depend upon:
1.pH of environment
2.Media components
–Agar depth, nutrients
3.Stability of drug
4.Size of inoculum
5.Length of incubation
6.Metabolic activity of organisms
(cont’d)

132. Antibiotic Susceptibility Testing
8 4 02 1
Tetracycline (μg/ml)
MIC = 2 μg/ml
Determination of MIC
Chl Amp
Ery
Str
Tet
Disk Diffusion Test

133. Resistance (cont.)
•Bacteria produce enzymes at or within the cell
surface –inactivate drug
•Bacteria possess impermeable cell membrane
prevent influx of drug.
•Transport mechanism for certain drug is energy
dependent-not effective in anaerobic
environment.
•ATB as organic acids penetration is pH –
dependent.